Focus: ACT Genomics is a Taiwan-based biotech company specializing in cancer genomic profiling and sequencing analysis. The company operates as a public-stage firm focused on oncology applications.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
ACT Genomics offers specialized oncology genomics expertise and public company credentials, but limited pipeline depth and hiring activity suggest this is a niche player best suited for genomics-focused scientists willing to accept slower growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for ACT Genomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from ACT Genomics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles